Expect AstraZeneca vaccine will be approved within days: UK NHS chief

Speaking at the FICCI's annual general meeting, David Prior said the pandemic paved way for whole new brand of research and development

AstraZeneca
He said the current crisis has shown countries how we are totally unprepared for the pandemic of this kind
Ruchika Chitravanshi New Delhi
2 min read Last Updated : Dec 12 2020 | 5:58 PM IST
After rolling out the Pfizer-BioNtech vaccine for coronavirus, Britain is hoping the approval for the Oxford-AstraZeneca’s shot will be given within a matter of days, David Prior, Chair of UK’s National Health Service said on Saturday.

“Next three months are going to be extremely difficult. Our hopes are pinned on the vaccine...We are hoping it will be approved within a matter of days.,” Prior said.

Speaking in the FICCI’s annual general meeting, Prior said that there has been a silver lining in the pandemic which has brought forth a whole new brand of research and development. 

He said the current crisis has shown countries how we are totally unprepared for the pandemic of this kind. On the other hand, it has also triggered extraordinary innovation. 

“We must win the public confidence in the efficacy and safety of the vaccine. This is why the regulatory process has to be independent.”

He also said that all around the world the health care systems have been struggling with the pandemic and it is not going to be manageable in the future.

“There has to be a fundamental change. and healthcare has to be more personalised. Going forward this revolution will be enabled by digitisation".

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

Next Story